Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may predict who faces memory loss after radiation

NCT ID NCT04638478

Knowledge-focused Sponsor: Maastricht Radiation Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study is testing whether advanced MRI scans can predict which meningioma patients will experience cognitive decline after radiotherapy. Researchers will follow 67 patients for two years, using cognitive tests and brain imaging before and after treatment. The goal is to identify brain regions most sensitive to radiation damage, so future treatments can be tailored to reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify patients at risk for memory and thinking problems after brain radiation, leading to more personalized and safer treatment plans.
What could go wrong
This is a small, early-stage observational study (67 participants) that aims to find patterns, not test a treatment. It may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 67 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult (18 years or older) patients with meningioma tumours (WHO I) in a good clinical condition treated with curative intend using radiotherapy (proton or photon) without other known malignancies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meningioma WHO I, grading based on pathology or radiological features * Age ≥ 18 years. * Karnofsky Performance Score 70 or above. * Ability to comply with the protocol, including neuropsychological testing and imaging. * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician. * Written informed consent. Exclusion Criteria: * Resection meningioma \< 3mnd * Age \< 18 years * Pregnancy * Any prior cranial radiotherapy * Any prior chemotherapy in the last 5 years * Contra-indication for MR imaging (i.e. metal implants, claustrophobia) * Any other serious medical condition that could interfere with follow-up. * Severe aphasia or language barrier interfering with assessing endpoints (i.e. completion of questionnaires or neurocognitive performance)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningioma

Contacts and locations

Locations

  • Maastricht Radiation Oncology

    Maastricht, Limburg, 6202 AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.